Literature DB >> 32037574

Early onset epileptic encephalopathy caused by novel compound heterozygous mutation of WWOX gene.

Tangfeng Su1, Yu Yan2, Shuang Xu1, Ke Zhang1, Sanqing Xu1.   

Abstract

The human WW domain containing oxidoreductase (WWOX) gene has been identified as a tumor suppressor gene. However, recent reports have demonstrated its dominant role in autosomal recessive disorders of the central nervous system, especially in early onset epileptic encephalopathy. Here, we report a Chinese case with novel compound heterozygous mutation of WWOX gene (c.229_230+2del mutation originated from her mother and c.1065dup (p.Ala356Serfs*173) variation from her father), and compare them to previously reported 59 WWOX-related epileptic encephalopathy (WOREE). Early onset and frequent epileptic seizures in the postnatal period, hypsarrhythmia patterns in EEG background and retarded development are the most important characteristics of WOREE in infants. Although the seizures in our case can be controlled by phenobarbital and topiramate, the prognosis of WOREE is poor.
© 2020 ISDN. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  early onset epileptic encephalopathy; oxidoreductase containing WW domain

Mesh:

Substances:

Year:  2020        PMID: 32037574     DOI: 10.1002/jdn.10013

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  3 in total

Review 1.  WWOX and metabolic regulation in normal and pathological conditions.

Authors:  Izabela Baryła; Katarzyna Kośla; Andrzej K Bednarek
Journal:  J Mol Med (Berl)       Date:  2022-10-22       Impact factor: 5.606

2.  De novo DYNC1H1 mutation causes infantile developmental and epileptic encephalopathy with brain malformations.

Authors:  Tangfeng Su; Yu Yan; Qingqing Hu; Yan Liu; Sanqing Xu
Journal:  Mol Genet Genomic Med       Date:  2022-01-31       Impact factor: 2.183

Review 3.  WWOX-Related Neurodevelopmental Disorders: Models and Future Perspectives.

Authors:  Daniel J Steinberg; Rami I Aqeilan
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.